PAK2 and breast cancer: Furthermore, in orthotopic breast cancer mouse models, systemic administration of FRAX597 not only suppressed primary tumor growth but also markedly diminished the metastatic burden in the lungs, reinforcing the potential clinical utility of PAK2 inhibition.